RT @OncBrothers@twitter.com

3. #E2211: Not at GI23 today but final manuscript is availble. Capecitabine + Temozolomide or Temozolomide alone in pts w/ advanced pNET after 1L progression, Ph2, N=144

- mOS 58.7mos vs 53.8mos (HR0.82)
- mPFS 22.7mos vs 14.4mos (HR0.58)

https://twitter.com/PamelaKunzMD/status/1616892624350351360

🐦🔗: https://twitter.com/OncBrothers/status/1616940787471728648

RT @OncBrothers@twitter.com

Day 3 #GI23 Highlights #CommunityOncology

1. #MOUNTAINEER: Tucat+Trast approved CRC

2. #SUNLIGHT: TAS102+Bev confirmed late option CRC

3. #E2211: Cape+Tem in pNET manuscript

4. #ctDNA kinetics CRC

5. TNT state in RectalCA

@ASCO@twitter.com #OncEd #MedEd @OncoAlert@twitter.com #GISM #MedTwitter

🐦🔗: https://twitter.com/OncBrothers/status/1616940781562134534